Business Wire

New Study: Hand Dryers Equally Hygienic to Paper Towels for Drying Hands

10.9.2020 22:16:00 EEST | Business Wire | Press release

Share

After an exhaustive two-year process, a University of Arizona Health Sciences research team have announced the publication of their work, Comparison of electric hand dryers and paper towels for hand hygiene: a critical review of the literature. The review culled the current breadth of data, including published studies, news reports and online content, seeking to uncover which hand drying method, hand dryers or paper towels, is more hygienic and safer relative to human health risks. The researchers found that, while studies in the public arena generally favor paper towels over hand dryers, the conclusions are largely misleading and unsubstantiated.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005927/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New study: hand dryers equally hygienic to paper towels for drying hands; Findings support World Health Organization and Centers for Disease Control and Prevention hand washing recommendations (Photo: Business Wire)

Through the scientific research, the use of hand dryers and paper towels to dry hands were found to be equal from a health and safety perspective; the findings echo recommendations from the World Health Organization that everyone “frequently clean [their] hands…” and “dry [them] thoroughly by using paper towels or a warm air dryer,” and the Centers for Disease Control and Prevention that report that, “Both [clean towels or air hand dryers] are effective ways to dry hands.”

To conduct the study, the research team considered 293 papers and published studies for inclusion in their review, rejecting 270 for failing to meet review criteria or for reporting generalized recommendations without sufficient scientific evidence. The 23 peer-reviewed studies that met the inclusion criteria were categorized and prioritized based on their scientific rigor, a score determined by taking into account such factors as sample size, methodology, data quality and whether or not the study was set up to represent real-world scenarios.

The study that was found to have the highest rigor score was an independent study conducted by the Mayo Clinic, Effects of 4 Hand-Drying Methods for Removing Bacteria From Washed Hands: A Randomized Trial . It found that “…there is no difference in bacteria counts when drying with paper towels or hand dryers.” Only three studies received positive rigor scores for having realistic testing conditions, and none of the studies reported any negative effects of either hand drying method on human health.

Although numerous studies have been published evaluating the “best” method for hand drying, “best” has been defined in a variety of ways relative to bacterial removal efficacy, environmental contamination potentials, ecological or cost benefits, noise and more. Kelly Reynolds, MSPH, Ph.D., the corresponding author of the review explained that, “No study to date has examined the “best” drying method,” and that she and her team, “found no empirical data to support one hand drying method over another from a health and safety perspective.”

In light of the coronavirus pandemic, hand hygiene has been widely covered in the media. Reynolds shared that, “Media reports frequently used sensationalized headlines. While such headlines may increase traffic, they sometimes overgeneralize or exaggerate research results. Consumers may only read the headlines which can influence public opinion toward biased or erroneous conclusions.”

“At a time when proper hand washing and drying is of the utmost importance, exclusively recommending paper towels is limiting, and frankly, irresponsible,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Hand dryers provide an effective way to achieve completely dry hands, a critical part of proper hand hygiene, the top defense against the spread of germs, like coronavirus.”

The scoping review’s conclusion calls for future studies to examine the relationship between contamination that occurs due to hand-drying methods and human health outcomes. They offer that this can be accomplished by utilizing real-world scenarios while controlling certain variables.

“We hope these credible findings will be consulted as part of guidelines and reopening plans,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Sensationalized news accounts and click-bait headlines created an unsubstantiated concern around hand dryers and hygiene. We’re grateful to the researchers for uncovering the truth, and hope the findings will help to dispel myths and categorize hand dryers as the hygienic hand drying solution they are.”

About Excel Dryer, Inc.

Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Twarog or Michelle Abdow
(Office) 413-787-1133
ltwarog@marketmentors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye